Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

Health Secretary Robert F. Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on Wednesday, ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

Notably, Novavax’s Nuvaxovid is the only non-mRNA-based vaccine in the United States. The NVAX vaccine was recently granted full approval by the FDA for use in older adults aged 65 and above ...

This is the same limited use the FDA set in licensing the Novavax COVID-19 vaccine last month. This fall, Moderna anticipates offering both Spikevax and mNexspike as COVID-19 vaccines. Their ...

The FDA stressed that this is not considered a replacement for the company’s existing shot but can be considered as a second option. Moderna’s new COVID-19 vaccine, named mNexspike ...